Company profile for Fareva

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Fareva’s API division has special technologies for high potent APIs (HPAPIs) down to the OEB-6 level, aseptic crystallization (sterile APIs), Spray Drying etc, with volumes ranging from a few kgs to multi tons production.
Fareva’s Drug Product division offers different technologies: injectables (lyophilized, solution, suspension, vial, ampoules, pre-filled syringes), unidoses and multidoses BFS, solids (tablets, hard ...
Fareva’s API division has special technologies for high potent APIs (HPAPIs) down to the OEB-6 level, aseptic crystallization (sterile APIs), Spray Drying etc, with volumes ranging from a few kgs to multi tons production.
Fareva’s Drug Product division offers different technologies: injectables (lyophilized, solution, suspension, vial, ampoules, pre-filled syringes), unidoses and multidoses BFS, solids (tablets, hard capsules, powders), semi-solids (cream, gel suppositories) and liquids (oral and external, sprays, aerosols).

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Luxembourg
Address
Address
28 place de la gare, 1616 Luxembourg
Telephone
Telephone
+49 16090545489
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

CPhI South East Asia

Not Confirmed

envelop Contact Supplier

CPhI South East Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

INTERVIEW #SpeakPharma

[Sponsored by another company]
Alchem NicSelect™ grants customers royalty-free access to T-MAX™ tech for 3-in-1 vape satisfaction in flavour-restricted markets
With increasing flavour bans in key markets, vaping brands are facing significant challenges in providing satisfying alternatives to vapers and smokers looking to transition. Recognising this need, Alchem NicSelect™ is making a bold move by offering its key customers royalty-free and unrestricted geographical access to its revolutionary T-MAX™ technology.“At Alchem NicSelect™, we understand the urgency for vaping brands to adapt to new regulations without compromising on satisfaction. By offering royalty-free access to T-MAX™ technology, we empower our customers to provide the closest cigarette-like experience possible, even in markets with strict flavour restrictions,” said Riccardo Santambrogio, Europe Sales Manager.HIGHLIGHTS// offering royalty-free access to T-MAX™ technology/ unrestricted geographical access/ closest cigarette-like experience Addressing the biggest barrier: Nicotine satisfactionOne of the primary reasons many vapers are dissatisfied and smokers struggle to switch to vaping is that traditional nicotine solutions fail to replicate the rapid satisfaction provided by cigarettes. Nicotine replacement therapies (NRTs) and even conventional vaping products often lack the immediate nicotine hit, throat feel, and overall experience that smokers are accustomed to. T-MAX™ solves this problem by engineering a nicotine experience that closely mimics cigarette consumption without relying on flavours.T-MAX™ provides a unique 3-in-1 approach:1. The Speed of a Cigarette – Rapid nicotine delivery and rush within seconds for immediate satisfaction.2. The Power of Nicotine Salts – A stronger perceived nicotine effect without exceeding legal limits (20 mg/ml nicotine limit under the European Tobacco Products Directive). With T-MAX™, 8 mg/ml feels like 20 mg/ml, and 14 mg/ml feels like 40 mg/ml.3. The Throat Hit of Freebase Nicotine – Especially in a flavour-free formulation, the combined ingredients in T-MAX™ deliver an even more satisfying throat feel than expected from nicotine base, much closer to and more familiar with a cigarette throat feel that habitual smokers recognise.HIGHLIGHTS// unique 3-in-1 approach/ rush within seconds/ stronger perceived nicotine effect without exceeding legal limits/ more satisfying throat feel that habitual smokers recogniseNo flavour, but not less satisfyingWhile flavours have traditionally played a role in vaping adoption, market realities are shifting. With flavour bans spreading across regions, brands need solutions that deliver satisfaction without relying on taste. Consumer research has shown that T-MAX™ performs exceptionally well even without added flavours. Since most cigarette smokers do not smoke for the tobacco flavour but rather for the nicotine hit and habitual experience, T-MAX™ provides a viable alternative that aligns with new regulatory landscapes.HIGHLIGHTS// flavour bans spreading across regions/ T-MAX™ performs exceptionally well even without added flavoursEmpowering vape brands with free access to T-MAX™By granting customers royalty-free access to the T-MAX™ technology, Alchem NicSelect™ is removing barriers for vaping brands and original equipment manufacturers (OEMs) looking to adapt to regulatory changes. This open-access approach ensures that manufacturers can integrate T-MAX™ into their product lines without additional costs, allowing them to offer superior nicotine satisfaction in markets where flavours are no longer an option.HIGHLIGHTS// removing barriers for vaping brands and OEMs looking to adapt/ manufacturers can integrate T-MAX™ into product lines without additional costsThe future of vaping in restricted marketsWith T-MAX™, the vaping industry has a powerful tool to retain customers and convert smokers who have struggled with traditional vaping products. By delivering the key elements of cigarette satisfaction — without combustion or flavours — T-MAX™ is set to redefine what a satisfying vape experience means in a post-flavour-ban world.“Our commitment to innovation and accessibility means we are providing our customers with the solutions they need to navigate an evolving regulatory landscape. T-MAX™ allows brands to offer a highly satisfying experience that mimics smoking without relying on flavours. The message is clear: no flavour, but not less satisfying”, added Santambrogio.HIGHLIGHTS// powerful tool to retain customers and convert smokers/ delivering the key elements of cigarette satisfaction without combustion or flavours/ no flavour, but not less satisfying

Impressions: 1298

https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets

Radio Compass
06 May 2025

VLOG #PharmaReel

[Sponsored by another company]
This PharmaReel highlights Gentec Pharmaceutical's expertise in generic APIs, HPAPIs, and prostaglandins with more than 30 years of experience. Operating from EU-GMP-certified facilities, the company exports to over 70 countries worldwide.

Impressions: 179

read-more

DATA COMPILATION #PharmaFlow

[Sponsored by another company]
CDMO Activity Tracker: Veranova, Carbogen lead ADC investments; Axplora, Polfa Tarchomin, Famar expand European footprint
During the second quarter (Q2) of 2025, contract development and manufacturing organizations (CDMOs) made substantial investments in specialized therapeutic manufacturing. The quarter also saw CDMOs pursue high-value, complex manufacturing niches, particularly in antibody-drug conjugates (ADCs), cell and gene therapies (CGTs) and oligonucleotides.Alongside these trends, Q2 also saw CDMOs strengthen their footprint in the United States amid concerns over rising tariffs and unpredictable trade policies being enforced by the Trump administration.Regeneron Pharmaceuticals committed over US$ 3 billion through a 10-year agreement with Fujifilm Diosynth Biotechnologies to nearly double its US manufacturing capacity for biologics. Under this agreement, Fujifilm will manufacture and supply drug products for Regeneron at its large-scale facility in Holly Springs, North Carolina.Thermo Fisher Scientific announced plans to invest an additional US$ 2 billion in the US over four years, reinforcing its manufacturing and R&D capabilities. With 64 facilities spread across 37 states, Thermo Fisher aims to bolster American innovation and competitiveness. Similarly, Piramal Pharma announced a US$ 90 million investment plan for expanding two facilities in the US, thereby bringing its total investment in the country to US$ 570 million. View CDMO Activity Tracker for Q2 2025 (Free Excel Available)Veranova, Carbogen lead ADC wave; Axplora doubles down on HPAPI production in ItalyThe quarter saw substantial investments in ADC manufacturing. Veranova announced a US$ 20 million investment in bioconjugation development and cGMP manufacturing capacity at its Devens, Massachusetts campus. With this investment, Veranova will be able to provide a more comprehensive suite of services to its partners developing ADCs and other bioconjugates. Veranova’s total investment in the Devens facility now stands at over US$ 50 million. Swiss CDMO Carbogen announced a US$ 31 million co-investment with an unnamed Japanese investor to expand its capabilities across its Aarau and Neuland (Switzerland) facilities. The facility will address increasing demand for complex and high-value compounds such as ADC drug linkers.Axplora announced a further €35 million (US$ 41 million) expansion of its Farmabios site in Italy, doubling the facility to approximately 108,000 square meters by mid-2026. This investment raises its total spend on the site to over €80 million (US$ 94.05 million) since 2019, supporting the production of highly potent active pharmaceutical ingredients (HPAPIs). Farmabios now stands as a key hub in Axplora’s global CDMO network.Polish pharmaceutical manufacturer Polfa Tarchomin is positioning itself as a significant player in the European CDMO market through its investment in the Center for Development and Production of Highly Potent Drugs. This 12,000 square meter facility has two state-of-the-art production lines designed for filling vials and pre-filled syringes with an annual capacity of 26 million product units.Skyepharma’s projected annual revenues from oncology-linked activities touched €10 million (US$ 11.2 million). The CDMO’s facility in Saint-Quentin-Fallavier is equipped to handle cytotoxic and cytostatic compounds, and is one of the few facilities in France capable of managing HPAPIs for oral anticancer treatments. View CDMO Activity Tracker for Q2 2025 (Free Excel Available) Athena acquires Medipha Santé, Famar buys MiP Pharma’s German site to strengthen European footprintDuring the quarter, several CDMOs enhanced their strategic capabilities through M&As. Athena Pharmaceutiques acquired  Medipha Santé to build a fully integrated pharmaceutical services platform in Europe. Based in Paris, Athena has strengthened its commercial and regulatory toolbox by bringing aboard Medipha Santé’s 35-strong team, which supports over 100 partner organizations and files approximately 350 dossiers annually with ANSM and other European agencies. With this integration, Athena positions itself as a one-stop CDMO partner.With the acquisition of MiP Pharma’s sterile manufacturing site in Homburg, Germany, the Famar Group has expanded its capabilities in aseptic and lyophilized fill-and-finish operations. The acquisition has strengthened Famar’s position in sterile drug manufacturing. The CDMO now has seven manufacturing facilities in Europe.PCI Pharma Services’ acquisition of Ajinomoto Althea has established a world-class, large-scale manufacturing hub in the San Diego region with state-of-the-art aseptic facilities for prefilled syringes, cartridges and high-potent formulations such as ADCs. PCI Pharma is now amongst the few US-based CDMOs capable of comprehensive ADC manufacturing.Samsung Biologics’ strategic spinoff of its biosimilar business stood out as a significant corporate restructuring exercise during the quarter. The separation of Samsung Bioepis, tentatively renamed Samsung Epis Holdings, aims to enhance Samsung Biologics’ strategic focus and build client trust, as it eliminates potential conflicts between CDMO services and proprietary drug development. The move came after Samsung Biologics inked a contract worth 737.3 billion Korean won (US$ 518 million) with an undisclosed US pharmaceutical company.WuXi Biologics announced a US$ 167 million divestment of its German facility to Terumo and broke ground on a microbial production plant in China. National Resilience, which was launched five years ago as the US drug manufacturer dedicated to broadening access to medicines and protecting biopharma supply chains, said it is shuttering six of its 10 facilities. The company said the sites were “not being fully utilized.” View CDMO Activity Tracker for Q2 2025 (Free Excel Available) MilliporeSigma, Simtra form 5-year ADC alliance; Silexion partners Catalent for siRNA developmentMerck KGaA’s MilliporeSigma and Simtra struck a five-year strategic alliance, combining expertise across the ADC value chain to reduce development timelines and complexity for biopharmaceutical companies. Viralgen collaborated with Trogenix to rapidly scale product supply for TGX-007, an AAV gene therapy for glioblastoma (a type of cancer of the brain and spinal cord).  Silexion announced a collaboration with Catalent for small interfacing RNA (siRNA) development and manufacturing. Catalent’s Limoges (France) facility will conduct formulation development and clinical manufacturing for Silexion’s SIL204 candidate, supporting both systemic and intra-tumoral delivery formulations.Skyepharma’s collaboration with Eneapharm through the Skyehub platform aims to support the treatment of patients suffering from exocrine pancreatic insufficiency, including those affected by cystic fibrosis or pancreatic cancer. Orion Corporation reached an agreement with Shilpa Biocare for the distribution of recombinant human albumin in Europe.Meanwhile, Aenova announced the launch of its Aenovation program, an initiative designed to fast-track early development of pharmaceutical formulations. The program addresses the critical challenges of bioavailability and time-to-market faced by poorly soluble drug candidates. View CDMO Activity Tracker for Q2 2025 (Free Excel Available) Our view The quarter saw CDMO developments mimic the broader trends in the pharmaceutical industry, such as onshoring of critical manufacturing capabilities in the US, consolidation of specialized expertise through strategic partnerships, and the relentless focus on emerging therapeutic modalities that promise to transform patient care. With CDMOs continuing to invest in next-generation manufacturing capabilities, we expect the sector to play a crucial role in drug innovation. 

Impressions: 341

https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint

#PharmaFlow by PHARMACOMPASS
10 Jul 2025

NEWS #PharmaBuzz

read-more
read-more
Fareva Pilots New GMP Unit at Its Pau Site
Fareva Pilots New GMP Unit at Its Pau Site

16 Jun 2025

// CONTRACTPHARMA

https://www.contractpharma.com/breaking-news/fareva-pilots-new-gmp-unit-at-its-pau-site/

CONTRACTPHARMA
16 Jun 2025
FAREVA Adds New Sterile Pilot Unit in Pau
FAREVA Adds New Sterile Pilot Unit in Pau

16 Jun 2025

// PRESS RELEASE

https://www.fareva.com/en/news/fareva-strengthens-its-expertise-with-a-new-gmp-sterile-pilot-unit-in-pau

PRESS RELEASE
16 Jun 2025

https://www.fareva.com/en/news/fareva-strategic-investments-to-meet-the-growing-demand-for-sterile-pharmaceutical-products

PRESS RELEASE
12 Nov 2024
Our next beauty 2024 exhibitions
Our next beauty 2024 exhibitions

13 Aug 2024

// PRESS RELEASE

https://www.fareva.com/en/news/our-next-beauty-2024-exhibitions

PRESS RELEASE
13 Aug 2024

https://apiject.com/press-announcements/fareva-and-apiject-sign-a-licensing-agreement-to-create-a-france-based-500m-unit-annual-capacity-for-single-dose-prefilled-vaccine-injections/

PRESS RELEASE
10 Dec 2021

https://www.prnewswire.com/news-releases/fareva-and-apiject-sign-a-licensing-agreement-to-create-a-france-based-500m-unit-annual-capacity-for-single-dose-prefilled-vaccine-injections-301441485.html

PRNEWSWIRE
10 Dec 2021

Services

Upload your portfolio for free, ask us

Packaging

Click here to discover the service providers for Packaging

API Manufacturing

Click here to discover the service providers for API Manufacturing

Drug Product Manufacturing

Click here to discover the service providers for Drug Product Manufacturing

API & Drug Product Development

Click here to discover the service providers for API & Drug Product Development

Inspections and registrations

Upload your audits for free, ask us

ABOUT THIS PAGE

Contact Fareva and get a quotation

Fareva is a supplier offers 68 products (APIs, Excipients or Intermediates).

Find a price of Anastrozole bulk with DMF, CEP, JDMF offered by Fareva

Find a price of Bicalutamide bulk with DMF, CEP, JDMF offered by Fareva

Find a price of Doxazosin Mesylate bulk with DMF, CEP, JDMF offered by Fareva

Find a price of Estradiol bulk with DMF, CEP, JDMF offered by Fareva

Find a price of Estradiol Valerate bulk with DMF, CEP, JDMF offered by Fareva

Find a price of Methotrexate bulk with DMF, CEP, JDMF offered by Fareva

Find a price of Norethisterone Acetate bulk with DMF, CEP, JDMF offered by Fareva

Find a price of Tamoxifen Citrate bulk with DMF, CEP, JDMF offered by Fareva

Find a price of Temozolomide bulk with DMF, CEP, JDMF offered by Fareva

Find a price of Timolol Maleate bulk with DMF, CEP, JDMF offered by Fareva

Find a price of Baclofen bulk with DMF, JDMF offered by Fareva

Find a price of Bupivacaine Hydrochloride bulk with DMF, CEP offered by Fareva

Find a price of Busulfan bulk with DMF, CEP offered by Fareva

Find a price of Deferoxamine Mesylate bulk with DMF, JDMF offered by Fareva

Find a price of Ganciclovir bulk with DMF, JDMF offered by Fareva

Find a price of Haloperidol bulk with DMF, JDMF offered by Fareva

Find a price of Levothyroxine Sodium bulk with DMF, CEP offered by Fareva

Find a price of Methotrexate bulk with DMF, CEP offered by Fareva

Find a price of Mianserin Hydrochloride bulk with CEP, JDMF offered by Fareva

Find a price of Norethisterone bulk with DMF, CEP offered by Fareva

Find a price of Trazodone Hydrochloride bulk with DMF, JDMF offered by Fareva

Find a price of Acyclovir Sodium bulk with DMF offered by Fareva

Find a price of Anastrozole bulk with CEP offered by Fareva

Find a price of Baclofen bulk with DMF offered by Fareva

Find a price of Buspirone Hydrochloride bulk with DMF offered by Fareva

Find a price of Cevimeline Hydrochloride bulk with DMF offered by Fareva

Find a price of Deferoxamine Mesylate bulk with DMF offered by Fareva

Find a price of Estradiol Benzoate bulk with DMF offered by Fareva

Find a price of Ganciclovir Sodium bulk with DMF offered by Fareva

Find a price of Lanthanum Carbonate bulk with DMF offered by Fareva

Find a price of Mycophenolate Mofetil bulk with DMF offered by Fareva

Find a price of Ropivacaine Hydrochloride bulk with DMF offered by Fareva

Find a price of Timolol Maleate bulk with DMF offered by Fareva

Find a price of Trazodone Hydrochloride bulk with JDMF offered by Fareva

Find a price of Altrenogest bulk offered by Fareva

Find a price of Aripiprazole bulk offered by Fareva

Find a price of Avibactam Sodium bulk offered by Fareva

Find a price of Baclofen bulk offered by Fareva

Find a price of Bempedoic Acid bulk offered by Fareva

Find a price of Benzododecinium bromide bulk offered by Fareva

Find a price of Bicalutamide bulk offered by Fareva

Find a price of CAS 116539-55-0 bulk offered by Fareva

Find a price of CAS 108436-36-8 bulk offered by Fareva

Find a price of Clomiphene Citrate bulk offered by Fareva

Find a price of Deracoxib bulk offered by Fareva

Find a price of Epinastine Hydrochloride bulk offered by Fareva

Find a price of Eplerenone bulk offered by Fareva

Find a price of Estradiol bulk offered by Fareva

Find a price of Estradiol Benzoate bulk offered by Fareva

Find a price of Estradiol Cypionate bulk offered by Fareva

Find a price of Estradiol Valerate bulk offered by Fareva

Find a price of Firocoxib bulk offered by Fareva

Find a price of Hydrocortisone bulk offered by Fareva

Find a price of Levothyroxine Sodium bulk offered by Fareva

Find a price of Losartan Potassium bulk offered by Fareva

Find a price of Medroxyprogesterone Acetate bulk offered by Fareva

Find a price of Methotrexate bulk offered by Fareva

Find a price of Norethisterone Acetate bulk offered by Fareva

Find a price of Paroxetine Mesylate bulk offered by Fareva

Find a price of Pirenzepine bulk offered by Fareva

Find a price of Relebactam bulk offered by Fareva

Find a price of Relugolix bulk offered by Fareva

Find a price of Talazoparib bulk offered by Fareva

Find a price of Tamoxifen Citrate bulk offered by Fareva

Find a price of Temozolomide bulk offered by Fareva

Find a price of Tenapanor bulk offered by Fareva

Find a price of Trenbolone Acetate bulk offered by Fareva

Find a price of Fosaparepitant dimeglumine salt bulk offered by Fareva

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty